Rajeev M. Shah's Net Worth

$2.25 Billion

Who is Rajeev M. Shah?

Rajeev M. Shah has an estimated net worth of $2.25 Billion. This is based on reported shares across multiple companies, which include AN2 Therapeutics, Inc., RHYTHM PHARMACEUTICALS, INC., Vaxcyte, Inc., iTeos Therapeutics, Inc., Mineralys Therapeutics, Inc., Cytek Biosciences, Inc., PMV Pharmaceuticals, Inc., Nkarta, Inc., DICE Therapeutics, Inc., Icosavax, Inc., Tyra Biosciences, Inc., MIRAGEN THERAPEUTICS, INC., Inhibrx, Inc., RxSight, Inc., Phathom Pharmaceuticals, Inc., Dyne Therapeutics, Inc., TG THERAPEUTICS, INC., Eliem Therapeutics, Inc., KalVista Pharmaceuticals, Inc., Vor Biopharma Inc., Verastem, Inc., Janux Therapeutics, Inc., Aerovate Therapeutics, Inc., Forma Therapeutics Holdings, Inc., Therapeutics Acquisition Corp., Synthorx, Inc., Eidos Therapeutics, Inc., Acumen Pharmaceuticals, Inc., 89bio, Inc., Solid Biosciences Inc., Inozyme Pharma, Inc., Pandion Therapeutics, Inc., Iterum Therapeutics plc, Kala Pharmaceuticals, Inc., Orchard Therapeutics plc, Satsuma Pharmaceuticals, Inc., Akouos, Inc., Black Diamond Therapeutics, Inc., Cardiff Oncology, Inc., Werewolf Therapeutics, Inc., Enliven Therapeutics, Inc., Ra Pharmaceuticals, Inc., Wave Life Sciences Ltd., Fulcrum Therapeutics, Inc., scPharmaceuticals Inc., ARS Pharmaceuticals, Inc., PepGen Inc., and Acrivon Therapeutics, Inc..

SEC CIK

Rajeev M. Shah's CIK is 0001619841

Past Insider Trading and Trends

2022 was Rajeev M. Shah's most active year for acquiring shares with 89 total transactions. Rajeev M. Shah's most active month to acquire stocks was the month of May. 2021 was Rajeev M. Shah's most active year for disposing of shares, totalling 44 transactions. Rajeev M. Shah's most active month to dispose stocks was the month of May. 2020 saw Rajeev M. Shah paying a total of $380,510,856.12 for 50,220,677 shares, this is the most they've acquired in one year. In 2020 Rajeev M. Shah cashed out on 134,050,196 shares for a total of $1,603,221,525.90, their largest year based on trade value.